Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes

Fu, Yang; Sun, Jie; Lian, Shizhen; Deng, Xiaoyu; Zhang, Lei; Shao, Jingyuan; Yu, Hao; Yan, Xijun; Zhu, Yanzhu

doi:10.3389/fvets.2022.678671

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum samples collected from the pigs were heat-inactivated at 56°C for 0.5 hours. To detect neutralizing antibodies, 150 TCID 50 /mL of PRRSV was added to DMEM with 2% FBS, followed by successive 2-fold dilutions of the test sera ( Fu et al., 2022 ), and incubated for one hour at 37°C. The mixture was then applied to monolayers of MARC-145 cells, which were cultured for four days at 37°C under 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

Zhao

Zhang²,

Sun³

et al. 2022

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

The porcine reproductive and respiratory syndrome virus (PRRSV) is a threat to the health of pigs worldwide, but commercially available vaccines offer limited protection against PRRSV infection. It is necessary to develop a more effective DNA vaccine. The immunological effects of DNA vaccines with three adjuvants were examined in pigs (Susscrofa domestica) challenged with PRRSV. These DNA vaccines, which encoded PRRSV GP3 and GP5, were formulated with A1, A2, and A3. Serum specific and neutralizing antibodies, IL-4, IFN-γ, IL-2, IL-10, CD4+ and CD8+T-lymphocytes, health status, histopathology, and viral loads were determined. The results showed that the use of adjuvant A3 led to higher levels of neutralizing antibodies and a lower viral load in pigs compared to the other adjuvants. The neutralizing antibody titers of the pVAX-GP35+A1 and pVAX-GP35+A3 groups reached a peak of 1:19 at 35 dpi. The maximum concentration of IL-4 was 136.77 pg/mL in the pVAX-GP35+A3 group. At 35 dpi, the IFN-γ concentration in the pVAX-GP35+A1 group was 227.4 pg/mL. pVAX-GP35+A3 group shows the highest IL-2 and IL-10 expression to the peak of 597.6 pg/mL and 189.1 pg/mL, respectively. We found a formulation demonstrated beneficial immune outcomes. This study provides an alternative vaccine to protect pigs from PRRSV.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

Zhao

Zhang²,

Sun³

et al. 2022

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

Immunogenicity of a novel inactivated canine adenovirus type 2 variant vaccine for dogs

Yang,

Ahn,

Lee

et al. 2024

Clin Exp Vaccine Res

View full text Add to dashboard Cite

Purpose The immunogenicity of vaccines containing the canine adenovirus (CAdV) type 2 (CAdV-2) variant has not yet been reported. We prepared a novel inactivated CAdV-2 variant vaccine using the CAV2232-41 strain, and evaluated its safety and immunogenicity in raccoon dogs. Materials and Methods The growth kinetics of CAV2232-41 were determined using Madin-Darby Canine Kidney (MDCK) cells. The nucleotide sequences of CAV2232 and CAV2232-41 were determined by next-generation sequencing. To generate the CAdV-2 variant vaccine, CAV2232-41 propagated in the MDCK cells was inactivated with 0.1% formaldehyde. Two vaccines were prepared by blending inactivated CAV2232-41 with Cabopol and Rehydragel adjuvants. Safety and immunogenicity of the CAV2232C and CAV2232R vaccines were evaluated in guinea pigs. Safety and immunogenicity of the CAV2232C vaccine were also evaluated in raccoon dogs. The virus neutralizing antibody (VNA) titer against CAV2232-41 was measured in sera collected from immunized guinea pigs and raccoon dogs. Results CAV2232-41 showed the highest viral titer on days 4–6 post-inoculation and had a deletion in the E3 gene, which was confirmed as a CAdV-2 variant. Guinea pigs inoculated with CAV2232C showed slightly higher VNA titers than those inoculated with CAV2232R 2 weeks after booster vaccination. Raccoon dogs immunized with the CAV2232C vaccine developed high mean VNA titers, while non-vaccinated raccoon dogs were antibody-negative. Conclusion The CAV2232C vaccine is safe and induces a protective VNA titer in raccoon dogs.

show abstract

Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes

Cited by 2 publications

References 20 publications

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

Immunogenicity of a novel inactivated canine adenovirus type 2 variant vaccine for dogs

Contact Info

Product

Resources

About